Last reviewed · How we verify
Triptorlin or Leuprorelin — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Triptorlin or Leuprorelin (Triptorlin or Leuprorelin) — Ruijin Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Triptorlin or Leuprorelin TARGET | Triptorlin or Leuprorelin | Ruijin Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Triptorlin or Leuprorelin CI watch — RSS
- Triptorlin or Leuprorelin CI watch — Atom
- Triptorlin or Leuprorelin CI watch — JSON
- Triptorlin or Leuprorelin alone — RSS
Cite this brief
Drug Landscape (2026). Triptorlin or Leuprorelin — Competitive Intelligence Brief. https://druglandscape.com/ci/triptorlin-or-leuprorelin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing